Pricing Log in Create free account
Sunday 8 November 2026 Export OGN’s income statement to Excel — free account

Organon & Co.

OGN

Healthcare Drug Manufacturers General

Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.

Revenue
−1.75%
EPS
+1.64%
Free cash flow
+118.8%
Total debt
−3.10%

Quarter to September 2026, against a year earlier

13.87 0.08 +0.58%
Market cap
$3.6B
P/E
17.3×
Fwd P/E
6.2×
Dividend yield
0.58%
F-score
5/9
ROIC
6.26%
Net debt / EBITDA
5.6×
Dividend safety
45/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Organon & Co. (OGN) EV/EBITDA

Alert me on EV/EBITDA

As of 6 November 2026, Organon & Co. (OGN) trades at a EV/EBITDA of 7.5×. Over the past ten years it has ranged from 3.3× (June 2021) to 9.6× (March 2022); the current reading is higher than 36% of that period. That is below the Drug Manufacturers General industry median of 14.7× and below the Healthcare sector median of 8.5×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 6.9× (4.54%)
FY2024 7.2× (8.51%)
FY2023 7.9× (8.01%)
FY2022 8.6× 2.76%
FY2021 8.4× 123.40%
FY2020 3.7× 0.00%
FY2019 3.7× 0.00%
FY2018 3.7× 0.00%
FY2017 3.7× —

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 7.5× (3.85%)
Jun 2026 7.8× 23.00%
Mar 2026 6.3× (8.48%)
Dec 2025 6.9× (2.14%)
23 more quarters

Against its own ten years

Low 3.3× High 9.6×
Ten-year median 7.8×
Current reading's percentile 36

EV/EBITDA against peers

Company EV/EBITDA
AMRN Amarin Corporation PLC compare 2.2×
NVO Novo Nordisk A/S compare 7.0×
OGN Organon & Co. 7.5×
GRFS Grifols, S.A. compare 8.4×
GSK GSK PLC Sponsored ADR compare 10.5×
PFE Pfizer Inc. compare 10.7×
BMY Bristol Myers Squibb Company compare 11.1×
SNY Sanofi compare 11.4×
BIIB Biogen Inc. compare 18.7×
Drug Manufacturers General industry median 14.7×
Healthcare sector median 8.5×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on OGN